Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hassan Website

Raffit Hassan, M.D.

Selected Publications

1)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
[Journal]
2)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
[Journal]
3)  Thomas A, Maltzman J, Hassan R.
Farletuzumab in lung cancer.
Lung Cancer. 80: 15-8, 2013.
[Journal]
4)  Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
Am. J. Pathol. 182: 1065-77, 2013.
[Journal]
5)  Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru DA.
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Clin. Cancer Res. 18: 858-68, 2012.
[Journal]
6)  Miller AC, Hassan R.
Clinical and pathological features are still the best determinants of prognosis in mesothelioma.
Oncology (Williston Park, N.Y.). 26: 1176, 1178, 1180, 2012.
[Journal]
7)  Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
PLoS ONE. 7: e31507, 2012.
[Journal]
8)  Kalra N, Zhang J, Yu Y, Ho M, Merino M, Cao L, Hassan R.
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Int J Cancer. [Epub ahead of print], 2012.
[Journal]
9)  Thomas A, Hassan R.
Immunotherapies for non-small-cell lung cancer and mesothelioma.
Lancet Oncol. 13: e301-10, 2012.
[Journal]
10)  Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R.
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
Anticancer Res. 32: 5151-8, 2012.
[Journal]
11)  Kelly RJ, Sharon E, Pastan I, Hassan R.
Mesothelin-targeted agents in clinical trials and in preclinical development.
Mol. Cancer Ther. 11: 517-25, 2012.
[Journal]
12)  Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M, Hassan R.
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Oncol. Rep. 27: 1794-800, 2012.
[Journal]
13)  Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012.
[Journal]
14)  Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R.
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.
Clin. Chem. Lab. Med. 50: 721-5, 2012.
[Journal]
15)  Kelly RJ, Sharon E, Hassan R.
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
Lung Cancer. [Epub ahead of print], 2011.
[Journal]
16)  Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I.
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.
Cancer Res. 71: 5915-22, 2011.
[Journal]
17)  Shin IS, Lee S, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH.
Effect of chelator conjugation level and injection dose on tumor and organ uptake of (111)In-labeled MORAb-009, an anti-mesothelin antibody.
Nucl Med Biol. [Epub ahead of print], 2011.
[Journal]
18)  Feng M, Zhang J, Anver M, Hassan R, Ho M.
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.
J Cancer. 2: 123-31, 2011.
[Journal]
19)  Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler DH.
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Clin. Cancer Res. 17: 3697-705, 2011.
[Journal]
20)  Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M.
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
PLoS ONE. 6: e14640, 2011.
[Journal]
21)  Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I.
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
Cancer Res. 70: 1082-9, 2010.
[Journal]
22)  Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I.
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Lung Cancer. 68: 455-9, 2010.
[Journal]
23)  Sarnovsky R, Tendler T, Makowski M, Kiley M, Antignani A, Traini R, Zhang J, Hassan R, FitzGerald DJ.
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Cancer Immunol. Immunother. 59: 737-46, 2010.
[Journal]
24)  Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Clin. Cancer Res. 16: 6132-8, 2010.
[Journal]
25)  Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH.
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Proc. Natl. Acad. Sci. U.S.A. 106: 3360-5, 2009.
[Journal]
26)  Hassan R, Schweizer C, Lu K, Schuler B, Remaley A, Weil S, Pastan I.
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Lung Cancer. [Epub ahead of print], 2009.
[Journal]
27)  Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I.
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Clin. Cancer Res. 15: 5274-9, 2009.
[Journal]
28)  Walshe JM, Gal A, Murray DR, Premkumar A, Berman D, Hassan R.
Malignant mesothelioma of the inguinal canal with an unusually long survival.
Am. J. Clin. Oncol. 31: 306-7, 2008.
[Journal]
29)  Hassan R, Ho M.
Mesothelin targeted cancer immunotherapy.
Eur. J. Cancer. 44: 46-53, 2008.
[Journal]
30)  Hassan R, Pass H.
Mesothelioma.
Physicians Information and Education Resource, American College of Physicians; http://pier.acpoline.org; 2007. In Press. [Book]
31)  Yan T, Hassan R, Welch L, Sugarbaker P.
Advances in diffuse malignant peritoneal mesothelioma.
Oncol. Rev. 1: 53-64, 2007.
[Journal]
32)  Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J.
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Clin. Cancer Res. 13: 7166-71, 2007.
[Journal]
33)  Zhang Y, Xiang L, Hassan R, Pastan I.
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Proc. Natl. Acad. Sci. U.S.A. 104: 17099-104, 2007.
[Journal]
34)  Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ.
Immunotoxin treatment of cancer.
Annu. Rev. Med. 58: 221-37, 2007.
[Journal]
35)  Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I.
Mesothelin expression in human lung cancer.
Clin. Cancer Res. 13: 1571-5, 2007.
[Journal]
36)  Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, Gruhn B, Pastan I.
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
Eur. J. Haematol. 79: 281-6, 2007.
[Journal]
37)  Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
Clin. Cancer Res. 13: 5144-9, 2007.
[Journal]
38)  Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L.
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Cancer Immun. 7: 20, 2007.
[Journal]
39)  Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang Q, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Bioconjug. Chem. 18: 773-784, 2007.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/11/2013.